[go: up one dir, main page]

LU90712I2 - Mal-ate de 5-(4-(n-m-thyl-n-(2-pyriddyl)amino)-thoxy)benzyl)) thiazolidinedione-2,4 dione ou ses sels pharmaceutiquement acceptables - Google Patents

Mal-ate de 5-(4-(n-m-thyl-n-(2-pyriddyl)amino)-thoxy)benzyl)) thiazolidinedione-2,4 dione ou ses sels pharmaceutiquement acceptables

Info

Publication number
LU90712I2
LU90712I2 LU90712C LU90712C LU90712I2 LU 90712 I2 LU90712 I2 LU 90712I2 LU 90712 C LU90712 C LU 90712C LU 90712 C LU90712 C LU 90712C LU 90712 I2 LU90712 I2 LU 90712I2
Authority
LU
Luxembourg
Prior art keywords
pyriddyl
thoxy
thiazolidinedione
thyl
dione
Prior art date
Application number
LU90712C
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10721461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90712(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of LU90712I2 publication Critical patent/LU90712I2/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LU90712C 1992-09-05 2001-01-10 Mal-ate de 5-(4-(n-m-thyl-n-(2-pyriddyl)amino)-thoxy)benzyl)) thiazolidinedione-2,4 dione ou ses sels pharmaceutiquement acceptables LU90712I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929218830A GB9218830D0 (en) 1992-09-05 1992-09-05 Novel compounds
PCT/GB1993/001853 WO1994005659A1 (fr) 1992-09-05 1993-09-01 Derives substitues de la thiazolidenedione

Publications (1)

Publication Number Publication Date
LU90712I2 true LU90712I2 (fr) 2001-03-12

Family

ID=10721461

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90712C LU90712I2 (fr) 1992-09-05 2001-01-10 Mal-ate de 5-(4-(n-m-thyl-n-(2-pyriddyl)amino)-thoxy)benzyl)) thiazolidinedione-2,4 dione ou ses sels pharmaceutiquement acceptables

Country Status (37)

Country Link
US (1) US5910592A (fr)
EP (2) EP0960883A1 (fr)
JP (5) JP2828777B2 (fr)
KR (3) KR20030097596A (fr)
CN (4) CN1040323C (fr)
AP (1) AP513A (fr)
AT (1) ATE182147T1 (fr)
AU (1) AU674880B2 (fr)
BR (1) BR1100916A (fr)
CA (2) CA2143849C (fr)
CY (1) CY2138B1 (fr)
CZ (2) CZ287473B6 (fr)
DE (2) DE10199002I2 (fr)
DK (1) DK0658161T3 (fr)
ES (1) ES2133410T3 (fr)
FI (2) FI982413A0 (fr)
GB (1) GB9218830D0 (fr)
GR (1) GR3030794T3 (fr)
HU (2) HU224212B1 (fr)
IL (1) IL106904A (fr)
LU (1) LU90712I2 (fr)
MA (1) MA22970A1 (fr)
MX (1) MX9305397A (fr)
MY (1) MY111190A (fr)
NL (1) NL300035I2 (fr)
NO (4) NO303016B1 (fr)
NZ (1) NZ255505A (fr)
PL (1) PL173725B1 (fr)
RU (3) RU2128179C1 (fr)
SA (1) SA93140245B1 (fr)
SG (2) SG83747A1 (fr)
SI (1) SI9300452B (fr)
SK (1) SK280777B6 (fr)
TW (1) TW385309B (fr)
UA (1) UA41901C2 (fr)
WO (1) WO1994005659A1 (fr)
ZA (1) ZA936509B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9308487D0 (en) * 1993-04-23 1993-06-09 Smithkline Beecham Plc Novel compounds
US5919782A (en) * 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973848B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
ZA973850B (en) * 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5801173A (en) * 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6372750B2 (en) 1996-07-01 2002-04-16 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
USRE39266E1 (en) * 1996-07-01 2006-09-05 Dr. Reddy's Laboratories, Limited Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
KR100579765B1 (ko) * 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US5885997A (en) * 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP0921798A1 (fr) * 1996-07-12 1999-06-16 Smithkline Beecham Plc Nouveau traitement contre la resistance a la leptine
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
CZ298469B6 (cs) * 1997-06-18 2007-10-10 Smithkline Beecham Plc Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
ATE353654T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und sulphonylurea
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
GB9721693D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
US20020006939A1 (en) * 1997-10-13 2002-01-17 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
US20010031776A1 (en) * 1997-10-13 2001-10-18 Smithkline Beecham P.L.C. Use of thiazolidinediones for the treatment of hyperglycaemia
GB9723295D0 (en) 1997-11-04 1998-01-07 Smithkline Beecham Plc Novel process
US7091359B2 (en) 1997-11-04 2006-08-15 Smithkline Beecham Plc Process for the preparation of thiazolidinedione derivatives
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
AU774613B2 (en) * 1997-12-16 2004-07-01 Smithkline Beecham Plc Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
AU770817B2 (en) * 1997-12-16 2004-03-04 Smithkline Beecham Plc 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,dione,maleic acid salt, hydrate as pharmaceutical
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
MA26662A1 (fr) * 1998-07-21 2004-12-20 Smithkline Beecham Plc Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
AP2001002036A0 (en) * 1998-07-21 2001-03-31 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
SK287038B6 (sk) 1998-11-12 2009-10-07 Smithkline Beecham Plc Farmaceutický prostriedok na postupné uvoľňovanie 5-[4-[2-(N- metyl-N-(2-pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu a metformínu a spôsob jeho výroby
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909075D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
ATE246191T1 (de) * 1999-04-23 2003-08-15 Smithkline Beecham Plc Polymorph von 5-(4-(2-(n-methyl-n-(2- pyrdyl)amino)äthoxy)benzyl)thiazolidin-2,4-dion maleinsäuresalz
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
JP2002543076A (ja) * 1999-04-23 2002-12-17 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用
BR0009934A (pt) * 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
JP2003507379A (ja) * 1999-08-17 2003-02-25 スミスクライン ビーチャム パブリック リミテッド カンパニー チアゾリジンジオン誘導体を含有する医薬組成物およびその調製法
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
GB0006133D0 (en) * 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
GB0014006D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
AP2002002688A0 (en) * 2000-06-16 2002-12-31 Smithkline Beecham Plc Treatment and prevention of cardiac insulin resistance associated associated conditions.
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2005229687B2 (en) * 2000-08-04 2008-03-13 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0019226D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
AU2005229688B2 (en) * 2000-08-04 2008-04-03 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
GB0019224D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021785D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel Pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
PL360661A1 (en) * 2000-09-26 2004-09-20 Dr.Reddy's Research Foundation Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US7241895B2 (en) 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
UA75370C2 (en) * 2000-09-26 2006-04-17 Reddys Lab Ltd Dr Polymorphic forms of 5-[4-[2(n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2.4-dione maleate
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
WO2002051839A1 (fr) * 2000-12-22 2002-07-04 Smithkline Beecham P.L.C. Mesylate de 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
WO2002051823A1 (fr) 2000-12-26 2002-07-04 Torrent Pharmaceuticals Ltd Procede de preparation de maleate de rosiglitazone
GB0127805D0 (en) 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
EP1446404B1 (fr) * 2001-11-21 2006-06-14 Smithkline Beecham Plc Edisylates de rosiglitazone et leur utilisation en tant qu'antidiabetiques
SI1448559T1 (sl) * 2001-11-21 2007-06-30 Smithkline Beecham Plc 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil-tiazolidin-2,4-dion- benzensulfonat; postopek za njegovo pripravo; njegovi polimorfi i, ii, iii; in njegova uporaba kot farmacevtska uäśinkovina
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0129851D0 (en) * 2001-12-13 2002-01-30 Smithkline Beecham Plc Novel compounds
WO2003050116A1 (fr) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Sel d'acide 10-camphorsulphonique de 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione et son utilisation contre le diabete sucre
WO2003050112A1 (fr) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Hydrates de toluenesulfonate d'un derive de thiazolidinedione
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130510D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
AU2002352479A1 (en) * 2001-12-20 2003-07-09 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
US8268352B2 (en) 2002-08-05 2012-09-18 Torrent Pharmaceuticals Limited Modified release composition for highly soluble drugs
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004062667A1 (fr) * 2003-01-08 2004-07-29 Dr. Reddy's Laboratories Limited Forme amorphe du maleate de rosiglitazone et procede de preparation
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
WO2005058813A2 (fr) * 2003-12-17 2005-06-30 Ranbaxy Laboratories Limited Agents antidiabetiques
EP1732513A2 (fr) * 2003-12-31 2006-12-20 Alpharma, Inc. Preparations de rosiglitazone
WO2005073227A2 (fr) * 2004-01-28 2005-08-11 Usv Limited Procede de preparation de maleate de 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione
GB2410948A (en) * 2004-02-13 2005-08-17 Sandoz Ag Novel phosphoric acid salt of rosiglitazone
AR047541A1 (es) * 2004-02-13 2006-01-25 Sandoz Ag Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
GB2421240A (en) * 2004-12-14 2006-06-21 Sandoz Ag Phosphoric acid salt of rosiglitazone
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
CZ296472B6 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
KR100749219B1 (ko) * 2006-03-15 2007-08-13 건일제약 주식회사 신규한 로지글리타존 옥살산염, 이의 제조방법, 및 이를포함하는 약제학적 조성물
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
BRPI0716134A2 (pt) 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
US7645616B2 (en) 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
EP1967182A1 (fr) * 2007-03-07 2008-09-10 KRKA, tovarna zdravil, d.d., Novo mesto Composition pharmaceutique comprenant un sel de rosiglitazone
WO2008149345A2 (fr) 2007-06-04 2008-12-11 Ben-Gurion University Of The Negev Research And Development Authority Composés triarylés et compositions les comprenant
CN101167726B (zh) * 2007-10-16 2011-05-18 宁夏康亚药业有限公司 马来酸罗格列酮分散片及其制备方法
PL384446A1 (pl) * 2008-02-12 2009-08-17 Adamed Spółka Z Ograniczoną Odpowiedzialnością Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
EP2184055A1 (fr) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Procédé de préparation de formes galéniques solides de maléate de rosiglitazone
DE102009053562A1 (de) 2009-11-18 2011-05-19 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
US20120094959A1 (en) 2010-10-19 2012-04-19 Bonnie Blazer-Yost Treatment of cystic diseases
CN102532122B (zh) * 2010-12-29 2015-12-02 开封制药(集团)有限公司 酒石酸罗格列酮的制备方法
CN106061940A (zh) 2013-11-05 2016-10-26 本古里安大学内盖夫研究发展局 治疗糖尿病和由其引发的并发疾病的化合物
US10034868B2 (en) 2014-11-04 2018-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
IT201800002630A1 (it) * 2018-02-13 2019-08-13 Giuliani Spa Composizione per la prevenzione e il trattamento dei disturbi della crescita dei capelli

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197297A (en) * 1976-11-17 1980-04-08 Smithkline Corporation 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines
US4405211A (en) * 1980-07-29 1983-09-20 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Liquid crystal compositions with pleochroic anthraquinone dyes
WO1986002073A1 (fr) * 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Derives de thiazolidinedione, procede de preparation et composition pharmaceutique les contenant
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5039687A (en) * 1985-12-04 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamine compounds having enhancing activity
SU1611216A3 (ru) * 1986-12-29 1990-11-30 Пфайзер Инк (Фирма) Способ получени производных тиазолидиндиона или их фармацевтически приемлемых солей с щелочными металлами
EP0306228B1 (fr) * 1987-09-04 1999-11-17 Beecham Group Plc Thiazolidinediones substituées
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
PL173725B1 (pl) 1998-04-30
BR1100916A (pt) 2000-07-04
DE69325658T2 (de) 1999-12-30
NL300035I1 (nl) 2001-03-01
NO974646L (no) 1995-03-03
HK1012363A1 (en) 1999-07-30
NZ255505A (en) 1997-08-22
FI982413L (fi) 1998-11-06
FI951004A0 (fi) 1995-03-03
IL106904A (en) 1997-09-30
HU224212B1 (hu) 2005-06-28
RU98117628A (ru) 2000-08-20
CN1101911A (zh) 1995-04-26
NO305802B1 (no) 1999-07-26
JP2828777B2 (ja) 1998-11-25
CN1183413A (zh) 1998-06-03
CN1183275A (zh) 1998-06-03
RU98117673A (ru) 2000-07-20
DE69325658D1 (de) 1999-08-19
EP0658161B1 (fr) 1999-07-14
KR950702982A (ko) 1995-08-23
CZ56595A3 (en) 1995-11-15
SG48302A1 (en) 1998-04-17
CZ290591B6 (cs) 2002-08-14
ES2133410T3 (es) 1999-09-16
NO950852D0 (no) 1995-03-03
IL106904A0 (en) 1993-12-28
SI9300452B (sl) 2003-02-28
MY111190A (en) 1999-09-30
CA2143849A1 (fr) 1994-03-17
NO303016B1 (no) 1998-05-18
UA41901C2 (uk) 2001-10-15
CA2273147A1 (fr) 1994-03-17
EP0960883A1 (fr) 1999-12-01
CN1051312C (zh) 2000-04-12
NO950852L (no) 1995-03-03
SI9300452A (en) 1994-06-30
CN1066939C (zh) 2001-06-13
EP0658161A1 (fr) 1995-06-21
TW385309B (en) 2000-03-21
HUT72639A (en) 1996-05-28
MA22970A1 (fr) 1994-04-01
KR20030097596A (ko) 2003-12-31
KR100371297B1 (ko) 2003-05-09
HU0500355D0 (en) 2005-05-30
JPH08501095A (ja) 1996-02-06
DE10199002I2 (de) 2001-12-13
RU2128179C1 (ru) 1999-03-27
DK0658161T3 (da) 1999-11-29
NL300035I2 (nl) 2001-07-02
CN1040323C (zh) 1998-10-21
NO2001005I2 (no) 2004-06-01
AU4973093A (en) 1994-03-29
ATE182147T1 (de) 1999-07-15
SK27795A3 (en) 1995-08-09
JP2002047288A (ja) 2002-02-12
US5910592A (en) 1999-06-08
CZ287473B6 (en) 2000-12-13
GR3030794T3 (en) 1999-11-30
KR20080081099A (ko) 2008-09-05
CN1063942C (zh) 2001-04-04
JP2004359676A (ja) 2004-12-24
HU9500659D0 (en) 1995-04-28
SK280777B6 (sk) 2000-07-11
AU674880B2 (en) 1997-01-16
CY2138B1 (en) 2002-06-21
JPH11147885A (ja) 1999-06-02
JP2008208142A (ja) 2008-09-11
NO2001006I1 (no) 2001-04-30
CA2143849C (fr) 2000-04-25
ZA936509B (en) 1994-06-16
FI951004L (fi) 1995-03-03
SG83747A1 (en) 2001-10-16
RU95108329A (ru) 1996-12-20
FI982413A7 (fi) 1998-11-06
AP9300562A0 (en) 1993-10-31
MX9305397A (es) 1995-01-31
WO1994005659A1 (fr) 1994-03-17
NO974646D0 (no) 1997-10-08
CN1183276A (zh) 1998-06-03
GB9218830D0 (en) 1992-10-21
FI106263B (fi) 2000-12-29
PL307812A1 (en) 1995-06-26
SA93140245B1 (ar) 2005-10-15
FI982413A0 (fi) 1998-11-06
AP513A (en) 1996-07-30

Similar Documents

Publication Publication Date Title
LU90712I2 (fr) Mal-ate de 5-(4-(n-m-thyl-n-(2-pyriddyl)amino)-thoxy)benzyl)) thiazolidinedione-2,4 dione ou ses sels pharmaceutiquement acceptables
PL300235A1 (en) 5-{2-[4-(1,2-benzoisothiazolyl-3)-1-piperozinyl] ethyl}-6-chloro-1,3-dihydro-2h-indolone-2 hydrochloride monohydrate
FI943164L (fi) 2-(1-(1,3-tiatsolin-2-yyli)atsetidin-3-yyli)tiokarbapeneemijohdannaisia
LU91131I2 (fr) Duloxétine et ses sels d'addition acides pharmaceutiquement acceptables, et en particulier, chlorhydrate de duloxétine.
DZ2220A1 (fr) Complexes d'inclusion de sels aryl-hétérocycliques.
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
ES2147836T3 (es) Derivados de 4,5-diariloxazol.
LU91136I2 (fr) 2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl)-méthoxy-3-hydroxy-1-propanyl-L-valinate et les sels pharmaceutiquement acceptables de celui-ci (valcyte).
AU656344B2 (en) N-(4-(5-(cyclopentyloxycarbonyl)-amino-1-methyl-indol- 3-ylmethyl)-3 methoxybenzoyl)-2-methylbenzene-sulphonamide
DE58906867D1 (de) Wässrige Dispersion von 2-(2'-Hydroxyphenyl-)benzotriazolen.
FI923774A7 (fi) 1,7-anellerade 2-(piperazinoalkyl)indolderivat samt foerfaranden och mellanprodukter foer deras framstaellning
FI952682L (fi) Insektisidisiä 5-substituoituja 2,4-diamiinipyrimidiinijohdannaisia
FI932868L (fi) 2'-deoxi-2'2'-difluor(2,6,8-substituerade) purinnukleosider med virus-och cancerhaemmande aktivitet, samt mellanprodukter
FI20010074A7 (fi) Terapeuttisesti aktiivisia 4-aryyli-3-(heteroaryyliureido)-1,2-dihydro-2-oksokinoliinijohdannaisia
PT790236E (pt) Pro-farmacos de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil-6-cloro-1,3-di-hidro-2h-indol-2-ona
FI933719L (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
NO20033184L (no) Anvendelse av forbindelsen (+)-<alfa>-(2,3-dimetoksyfenyl)-1- [2-(4-fluorfenyl)etyl]-4-piperidinmetanol
ZA964130B (en) Potentiation of the microbicide 2-(thiocyanomethylthio)- benzothiazole using an N-alkyl heterocyclic compound
ITGE940099A0 (it) Dispositivo per l'agugliatura di una falda di ovatta.
ITGE940106A0 (it) Dispositivo per l'agugliatura di una falda di ovatta.
DE69430905D1 (de) 4-(R)-1'-Formylethyl Azetidin-2-on-Derivate
FR2726854B1 (fr) Facade mobile notamment pour la fermeture d'espaces de rangement ou de meubles
FI955829A0 (fi) Heterosyklinen kemia
MX9205186A (es) Derivados de 4-[4-[4-(4-hidroxifenil)-1-piperazinil]-fenil]-5-metil-3h-1,2,4-triazo l-3-ona